JAK/STAT as therapeutic signaling pathway in leukemia: a systematic review on in vitro inhibitors

Author:

Karimi Zahed1,Shahvari Samira Zakeri1,Ghasemi Katayoon1,Faridpour Amir Abbas2,Baradaran Mohammad Amin3,Satarzadeh Mohammad1

Affiliation:

1. Hormozgan University of Medical Sciences

2. Arak University of Medical Sciences

3. Ardabil University of Medical Sciences

Abstract

Abstract

Object Janus kinases (JAKs), signal transducer and activator of transcription proteins (STATs) is a main signaling pathway in the immune system, autoimmune disease and in many malignancies such as leukemia. Limiting this signaling pathway has so far been investigated in the treatment of some diseases such as lymphoma, and in this systematic review, we will investigate the role of this type in leukemia. Method This systematic review was written based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the principle of non-bias was respected. All the articles from 2014–2024 were extracted from Web of Science, PubMed and Scopus databases. We extracted the extracting inhibitors, related immunity elements, JAK/STAT kind, side signaling pathway. Results Three authors searched the database, after screening full texts, 17 articles were included. 15 inhibitory drugs for the JAK/STAT pathway were extracted in studies, which inhibit this signaling pathway in vitro and in cultured human leukemic cells. The most signaling pathways in leukemia were limited to STAT 5 and STAT 3, which were inhibited by Thymoquinone, Ritanserin, Dactocilib and Ruxolitinib. On the other hand, leukemic cells act exclusively through the JAK 2 pathway, which was specifically inhibited by Ruxolitinib and AG490. Increased apoptosis of leukemic cells and decreased cell survival was the result of monotherapy and multitherapy of these inhibitors in the studies available to us. Conclusion Inhibition of JAK/STAT pathway is associated with the reduction of leukemic cell growth and apoptosis of these types of cells, which seems to be a great therapeutic potential for clinical studies in all types of leukemia. We suggest that future studies investigate this type of treatment especially in children and evaluate our results.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3